Willis Investment Counsel Cuts Holdings in Medpace Holdings, Inc. $MEDP

Willis Investment Counsel trimmed its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 23.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,590 shares of the company’s stock after selling 2,894 shares during the period. Willis Investment Counsel’s holdings in Medpace were worth $5,386,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Fifth Third Wealth Advisors LLC raised its position in shares of Medpace by 2.6% in the third quarter. Fifth Third Wealth Advisors LLC now owns 737 shares of the company’s stock worth $379,000 after acquiring an additional 19 shares during the period. BOKF NA raised its position in shares of Medpace by 0.8% in the third quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after acquiring an additional 20 shares during the period. HighPoint Advisor Group LLC raised its position in shares of Medpace by 2.8% in the third quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock worth $416,000 after acquiring an additional 22 shares during the period. Kaufman Rossin Wealth LLC raised its position in shares of Medpace by 3.4% in the fourth quarter. Kaufman Rossin Wealth LLC now owns 795 shares of the company’s stock worth $447,000 after acquiring an additional 26 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. raised its position in shares of Medpace by 35.1% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock worth $55,000 after acquiring an additional 27 shares during the period. 77.98% of the stock is owned by institutional investors.

Analyst Ratings Changes

MEDP has been the subject of a number of analyst reports. Truist Financial decreased their price objective on shares of Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a research report on Wednesday, February 11th. Mizuho set a $582.00 price objective on shares of Medpace in a research report on Wednesday, February 11th. Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Robert W. Baird upgraded shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price objective for the company in a research report on Tuesday, February 10th. Finally, Royal Bank Of Canada initiated coverage on shares of Medpace in a research report on Tuesday, March 3rd. They issued an “outperform” rating and a $522.00 price objective for the company. Four analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $486.67.

Insiders Place Their Bets

In related news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the transaction, the president directly owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. This trade represents a 67.88% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 20.30% of the company’s stock.

Medpace Trading Up 2.4%

Shares of Medpace stock opened at $520.65 on Thursday. The firm has a market capitalization of $14.87 billion, a PE ratio of 34.03, a P/E/G ratio of 2.39 and a beta of 1.39. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $628.92. The firm’s 50-day moving average price is $476.51 and its 200 day moving average price is $537.42.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. The firm had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. Medpace’s quarterly revenue was up 32.0% compared to the same quarter last year. During the same period last year, the company posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.